Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role of Novel PET Molecular Imaging Targeting Fibroblast Activation Protein in the Diagnosis of Hepatobiliary Malignancies

NCT05264688 is registered in ClinicalTrials.gov with Zhongnan Hospital as lead sponsor.

NCT NCT05264688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05264688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role of Novel PET Molecular Imaging Targeting Fibroblast Activation Protein in the Diagnosis of Hepatobiliary Malignancies
Lead sponsor
Zhongnan Hospital
Phase
Observational
Overall status
Unknown status
Start date
January 20, 2022
Completion date
October 31, 2022
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatobiliary diseases